HGSI Human Genome Sciences, Inc. (MM)

DALLAS, July 26, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Human Genome Sciences, Inc. (NASDAQ: HGSI) in connection with a buyout for $14.25 per share to GlaxoSmithKline PLC. Concerned HGSI investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies.

"Analysts have pegged the value of the company as high as $18.00 per share," Hamilton Lindley said. "Shareholders are owed the highest price reasonably available in a corporate buyout. Our potential shareholder claim seeks to ensure those fiduciary duties are enforced at the highest levels of the company."

Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. HGSI stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbllp.com or 877-583-2855 with questions or concerns.

Hamilton Lindley

Goldfarb LLP

2501 N. Harwood, Ste. 1801

Dallas, TX 75201

(877) 583-2855 Toll Free Telephone

(214) 583-2233 Local Phone Number

(214) 583-2234 Fax Number

www.goldfarbllp.com

SOURCE Goldfarb LLP